Cannabix Secures Australian Deal, Signals Strategic Shift from Funding to Sales

VANCOUVER, British Columbia – December 30, 2025 – By Mark Peterson

Cannabix Technologies Inc., a developer of advanced breath-testing technologies, has secured its first international distributor order for its BreathLogix alcohol screening devices, marking a pivotal entry into the Australian market. The deal with Breathalyser Sales & Service Pty Ltd. (“Breathalyser SSP”), a veteran distributor in the region, not only represents a significant commercial milestone but also signals a potential turning point in the company's financial strategy, as strong product interest prompts it to cancel a planned capital raise.

The order from Breathalyser SSP, which will be the exclusive distributor for Cannabix in Australia, New Zealand, and the Pacific Islands, is the first major validation of the BreathLogix system outside of North America. This development places Cannabix’s technology at the forefront of a global push towards smarter, autonomous workplace safety solutions.

“Cannabix is excited to receive first orders from Australia for its BreathLogix Alcohol devices as the Company works to deliver innovative new technologies to market,” stated Rav Mlait, CEO of Cannabix Technologies, in the official announcement. “Breathalyser Sales & Service Pty Ltd has many years of experience with various industries deploying breath alcohol testing systems to improve worker safety.”

The Rise of Autonomous Workplace Safety

The BreathLogix device is more than just a breathalyzer; it is a fully autonomous screening portal designed for the modern, high-stakes workplace. The system is engineered to operate without direct human supervision, providing rapid, pre-access alcohol checks to prevent impaired individuals from entering safety-critical environments. When a user blows into the device, it provides an instant Blood Alcohol Content (BAC) reading, simultaneously captures a photograph to confirm their identity, and logs the result in a secure cloud portal.

This integrated approach solves several key challenges for employers. If a test returns a positive BAC result, managers are alerted in real-time via SMS and email, enabling immediate intervention to prevent potential injuries or property damage. All test data is managed through a dedicated web portal, creating a comprehensive audit trail for compliance and incident reporting.

Further enhancing its utility, the BreathLogix system can be integrated with existing security infrastructure, including doors, turnstiles, and fleet vehicle key management systems. This allows companies to create automated checkpoints that physically prevent access until a successful breath test is completed. This capability is crucial for a wide range of scenarios, from start-of-shift screening and random testing to post-incident and return-to-work protocols.

Underpinning this technology is a recent U.S. patent granted to Cannabix for its “Contact-Free Breath Analysis Device and Method,” which covers innovations in dual-mode contactless breath capture. This technology is central to the unmanned, hygienic operation of the BreathLogix platform and highlights the company’s focus on creating user-friendly, scalable solutions.

A Strategic Foothold in a High-Stakes Market

The choice of Australia as the first international market for BreathLogix is highly strategic. The country’s robust industrial sector—particularly in mining, oil and gas, and logistics—is governed by some of the world's most stringent Work Health and Safety (WHS) regulations. In these high-risk environments, where a single error can have catastrophic consequences, there is zero tolerance for impairment. This creates a fertile ground for advanced screening technologies that are both effective and efficient.

The partnership with Breathalyser SSP provides Cannabix with immediate credibility and an established distribution network. Founded in 1986, Breathalyser SSP is recognized as Australia's oldest and a leading supplier of drug and alcohol testing equipment, serving a vast client base that includes law enforcement, public health agencies, and major industrial corporations.

Ben Smit, Managing Director of Breathalyser SSP, highlighted the market's readiness for such a solution. “Pre-access, unmanned employee alcohol screening is a major segment of our business,” he stated. “BreathLogix delivers several key features that are important to employers including the ability to rapidly test for breath alcohol, integration capabilities, replaceable sensor cartridge technology and cloud reporting to name a few.”

Technology as the Key Differentiator

While the Australian market features established competitors like Alcolizer Technology and Pathtech, Cannabix is betting on its technological innovations to carve out a significant share. The most prominent of these is its patent-pending pre-calibrated sensor cartridge technology.

Traditionally, breathalyzer maintenance is a costly and disruptive process. Devices must be taken out of service and sent to a technician for calibration to ensure accuracy, a particular challenge for companies operating in remote mining or industrial sites. The BreathLogix design circumvents this issue entirely. Administrators can simply swap out an old sensor cartridge for a new, pre-calibrated one in seconds, with no special equipment or technical expertise required. This feature dramatically reduces the total cost of ownership and maximizes device uptime—a critical selling point for any large-scale enterprise.

This focus on user-friendly maintenance, combined with the system's autonomous operation and deep integration capabilities, positions BreathLogix as a next-generation solution designed to reduce both risk and operational friction.

Financial Confidence and a New Outlook

Perhaps the most telling indicator of the company’s newfound momentum is its decision to cancel a previously announced non-brokered private placement intended to raise up to $2 million. For an early-stage company that has historically operated at a net loss while investing heavily in research and development, shelving a financing round is a significant move.

The company explicitly linked the decision to the positive commercial developments. According to its press release, “Recent orders for the BreathLogix product line, coupled with increased ramp-up activity from distribution partners for the Marijuana Breath Test solution, indicate that the Company’s near-term capital requirements will be reassessed in early 2026.”

This statement suggests a strategic pivot from reliance on dilutive equity financing towards a future funded by actual product sales. After years in the development phase, this first international order provides tangible evidence of market acceptance and a clear path to revenue. The move bolsters investor confidence by demonstrating that the company's technology is not just innovative in theory but commercially viable in practice. As Cannabix gains traction in Australia and continues to advance its marijuana breathalyzer technology, it appears to be transitioning from a speculative R&D firm into a commercial-stage enterprise with a validated product portfolio.